Today: The Nivalis Therapeutics Inc. (NVLS) gets Sell status at Zacks Investment Research

The Nivalis Therapeutics Inc. (NVLS) gets Sell status at Zacks Investment Research

Zacks Investment Research lowered shares of Nivalis Therapeutics Inc. (NASDAQ:NVLS) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

According to Zacks, “Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado. “

Other equities analysts also recently issued reports about the stock. Cowen and Company reiterated a buy rating on shares of Nivalis Therapeutics in a report on Monday, August 1st. HC Wainwright reiterated a buy rating on shares of Nivalis Therapeutics in a report on Monday, August 8th. Piper Jaffray Cos. reiterated a buy rating and set a $16.00 price target on shares of Nivalis Therapeutics in a report on Tuesday, August 30th. Finally, Raymond James Financial Inc. assumed coverage on shares of Nivalis Therapeutics in a report on Tuesday, September 13th. They set an outperform rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $13.75.

Nivalis Therapeutics (NASDAQ:NVLS) opened at 7.69 on Wednesday. Nivalis Therapeutics has a 52 week low of $3.68 and a 52 week high of $9.45. The company’s market cap is $119.22 million. The firm’s 50 day moving average is $7.65 and its 200-day moving average is $5.45.

Nivalis Therapeutics (NASDAQ:NVLS) last issued its quarterly earnings results on Monday, August 1st. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.03. On average, analysts predict that Nivalis Therapeutics will post ($2.29) earnings per share for the current fiscal year.

In other Nivalis Therapeutics news, EVP David Malcom Rodman sold 5,820 shares of the business’s stock in a transaction dated Tuesday, October 4th. The shares were sold at an average price of $7.96, for a total value of $46,327.20. Following the completion of the sale, the executive vice president now directly owns 18,056 shares of the company’s stock, valued at approximately $143,725.76. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.00% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. Paloma Partners Management Co bought a new stake in Nivalis Therapeutics during the second quarter valued at about $105,000. State Street Corp boosted its stake in Nivalis Therapeutics by 4.5% in the first quarter. State Street Corp now owns 44,495 shares of the company’s stock valued at $186,000 after buying an additional 1,900 shares during the period. Opaleye Management Inc. bought a new stake in Nivalis Therapeutics during the first quarter valued at about $417,000. AXA boosted its stake in Nivalis Therapeutics by 35.4% in the second quarter. AXA now owns 533,692 shares of the company’s stock valued at $2,455,000 after buying an additional 139,652 shares during the period. Finally, Sabby Management LLC boosted its stake in Nivalis Therapeutics by 31.5% in the first quarter. Sabby Management LLC now owns 662,058 shares of the company’s stock valued at $2,761,000 after buying an additional 158,463 shares during the period. 83.12% of the stock is owned by institutional investors.

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

Related posts

Leave a Comment